Navigation Links
Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension
Date:5/31/2012

MONMOUTH JUNCTION, N.J., May 31, 2012 /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved the first-ever generic to Delsym®, an extended-release oral liquid suspension containing dextromethorphan polistirex.

Delsym was approved in 1982 and there has never been any generic alternative approved until now. Tris has pioneered the delivery of drugs in taste-neutral, extended release dosage forms such as liquids, ODT/chewable tablets, and strips that are otherwise associated with immediate release. Tris' versatile, patented technology avoids the use of toxic organic solvents by employing aqueous-based coating.

"This is the third extended-release liquid product approved by the FDA based on our patented technology, and speaks to Tris' capabilities to develop and commercialize difficult products," said Ketan Mehta, President & CEO of Tris Pharma.  "Leveraging our technology, Tris has built a robust and deep pipeline of unique products that will address many of today's unmet needs."

Perrigo is Tris' exclusive partner in distributing this product as a store-brand alternative to Delsym, and has announced that it will be shipping the product for the coming cough/cold/flu season.  Annual sales across the entire Delsym brand are estimated at more than $100 million.

Delsym is a registered trademark of Reckitt Benckiser, which is not associated with Tris Pharma or Tris' generic product.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.


'/>"/>
SOURCE Tris Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
2. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
3. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
4. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
5. Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6
6. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
7. Isis Pharmaceuticals to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
9. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
10. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
11. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2019)... ... , ... James M. Barthel, CEO of MT2 Firing Range Services said, “MT2 ... lead into profit by giving the range owner/manager the highest value for their reclaimed ... highest value for their lead. No one reclaims more lead or pays more for ...
(Date:11/5/2019)... MONTCLAIR, N.J. (PRWEB) , ... November 05, 2019 ... ... San Antonio, 555 South Alamo Street in Texas will be a timely program ... instruction in the management of chronic pain. , The Texas Medical Board requires ...
(Date:11/5/2019)... ... November 05, 2019 , ... Ida Culver House Broadview announced today ... will result in the layoff of 147 full- and part-time workers, and 53 current ... will enable Ida Culver House Broadview to shift its care model to provide higher ...
Breaking Medicine Technology:
(Date:11/6/2019)... ... November 06, 2019 , ... Founder of the Trivedi Effect®, ... God of their understanding, as well as, to illuminate the path of awareness ... fate, and fortune. , The next Trivedi Effect® Online Workshop is scheduled ...
(Date:11/6/2019)... Va. (PRWEB) , ... November 06, 2019 , ... ... Thinking Skills and Innovative Techniques , to Improve Inspections, An FDAnews Workshop, Nov. ... Cause Analysis CAPA Investigations starts in one week. , Dear FDA-Regulated Executive, , ...
(Date:11/6/2019)... Germany (PRWEB) , ... November ... ... global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... and Chief Executive Officer, John Chiminski, has received the inaugural CPhI Pharma ...
(Date:11/5/2019)... SEATTLE (PRWEB) , ... November 05, 2019 , ... ... informed care strategies, announces Associate Managing Editor, Sabitha Rajan, MD, MSc, will be a ... Conference + Expo on Nov. 12, 2019, at 9:00 a.m., in Austin, Texas. ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... by PhillyCooke Consulting and FDAnews, Dec. 10-11, 2019 , Hilton Cabana Miami Beach ... World-Class Advertising and Promotion Review Program ends on Nov. 12. , Current ...
Breaking Medicine News(10 mins):